CUR, STEM, GERN, KOOL, CYTX, ASTM, ACTC, TNGN, BCLI..
All stem cell companies I know pale in comparison.
OncoCyte PanC patents to be confirmed, that will be huge factor. Technically genes can't be pAtented, but the proprietary gene marker method for testing can be. Once these patents come through all out buying blitz.
“The presentations on PanC-Dx™ at the AACR 2015 annual meeting will report on the first human clinical data from a key OncoCyte product development program,” said Joseph Wagner, PhD, OncoCyte’s Chief Executive Officer. “We, along with our clinical investigators, are pleased with the high sensitivity and specificity of PanC-Dx in diagnosing bladder cancer. The levels of accuracy that we report may give this new diagnostic the potential for widespread adoption as an improved method of detecting bladder cancer or its recurrence. We appreciate the effort of our clinical investigators and distinguished collaborators at Johns Hopkins University School of Medicine, leaders in bladder cancer research"
Those bash and buyers clowns have been using BTX as a chew toy for too long, later this year as we move above $10 and become more stable you will be seeing less of them guarenteed.
OncoCyte anti-tumor program top secret, would be fantastic if clinical trials started this year
Then you will see some real movement
BTX owns AST, seems lopsided now but will even out in one months time, hang in there!
PanC-DX has a home in top hospitals such as Weil Cornell and Cancer Institute in Spain
Chart lookin good, will likely surpass 2011 high of $10 after cancer diagnostics start come to market later this year.
Early details are scarce, with the company disclosing only that it plans to create cloud-based mobile health products and services leveraging big data to “construct a holistic picture of an individual’s health.” The effort will be helmed by Netflix, Netscape, and CAMERON | PACE Group veteran Corey Bridges who became CEO of LifeMap Sciences at the beginning of this year.
“The biggest reason for the scantiness of details is that we’re taking a show don’t tell attitude about this,” Bridges says. But with internal excitement building around the project and with and BioTime’s own reporting requirements as a public company, the team made the decision to pull the curtain back, if only slightly.
Where things get interesting, and a whole lot more credible, however, is when LifeMap announces who it’s recruited to participate. LifeMap today announced a development partnership with The Icahn School of Medicine at Mount Sinai. The effort will be led by world-renowned researcher, Dr. Eric Schadt, founding director of the Icahn Institute for Genomics and Multiscale Biology, who has been named LifeMap’s lead science advisor. Dr. Schadt is highly regarded for his expertise on the “generation and integration of very large-scale sequence variation, molecular profiling, and clinical data in disease populations for constructing molecular networks that define disease states and link molecular biology to physiology,” the company writes in a statement today.
“We’re not just working remotely with Mt. Sinai, sending a few emails back and forth,” Bridges says. “We will have a team of people working in their facility, cheek to jowl. This is an honest to god co-development partnership.”
Why does BTX need big pharma partner? PanC-DX is a simple blood/urine sample type test, Weill Cornell and OncoCyte might not need a middle man!
Just heard hospital in phili advertising genetic cancer testing on the radio. I think Weill Cornell is a great partner for BTX. Might not need a middle man with OnCoCyes PanC-DX!